Personalis (PSNL)
NASDAQ:PSNL
Want to see PSNL full AI Analyst Report?
PSNL Stock Chart & Stats
$6.73
-$0.70(-11.71%)
At close: 4:00 PM EST
$6.73
-$0.70(-11.71%)
Day’s Range― - ―
52-Week Range$3.84 - $11.50
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.47M
Market Cap
$605.04M
Enterprise Value$355.19M
Total Cash (Recent Filing)$239.95M
Total Debt (Recent Filing)$31.87M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
May 07, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding104,677,900
10 Day Avg. Volume1,330,569
30 Day Avg. Volume1,467,582
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-8.94
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue5.10
Enterprise Value/Gross Profit22.51
Enterprise Value/Ebitda-5.00
Forecast
1Y Price Target
$11.67Price Target Upside73.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$78.76M
Bulls Say, Bears Say
Bulls Say
Biopharma Partnerships And Revenue PotentialRobust biopharma interest and guidance for biopharma business growth point to potential revenue upside and improved gross margins as pharma partnerships scale and drive testing demand.
Clinical Volume GrowthSharply rising clinical test volumes and dramatically higher annual test counts signal accelerating market demand and stronger commercial traction for the company's diagnostic services.
Reimbursement And Medicare CoverageMedicare coverage for surveillance of breast cancer and non-small cell lung cancer expands the number of major covered indications for the NeXT Personal test, reducing commercial risk and supporting clinical revenue growth.
Bears Say
Below-Consensus GuidanceGuidance for the coming year was provided below analyst consensus, creating downside pressure on growth expectations and the stock's outlook.
Margin And Cash Burn PressurePrioritizing rapid clinical adoption ahead of full reimbursement increases commercial spending, lowers near-term gross margins, and widens operating losses, raising near-term cash burn risk.
Revenue Concentration And CompetitionDeclines in pharmaceutical testing and population sequencing revenue, coupled with competitive pressure from a rival, underscore reliance on a limited set of revenue sources and elevate execution risk.
Personalis News
PSNL FAQ
What was Personalis’s price range in the past 12 months?
Personalis lowest stock price was $3.84 and its highest was $11.50 in the past 12 months.
What is Personalis’s market cap?
Personalis’s market cap is $605.04M.
When is Personalis’s upcoming earnings report date?
Personalis’s upcoming earnings report date is May 07, 2026 which is in 3 days.
How were Personalis’s earnings last quarter?
Personalis released its earnings results on Feb 26, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.028.
Is Personalis overvalued?
According to Wall Street analysts Personalis’s price is currently Undervalued.
Does Personalis pay dividends?
Personalis does not currently pay dividends.
What is Personalis’s EPS estimate?
Personalis’s EPS estimate is -0.27.
How many shares outstanding does Personalis have?
Personalis has 104,677,900 shares outstanding.
What happened to Personalis’s price movement after its last earnings report?
Personalis reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went up 0.332%.
Which hedge fund is a major shareholder of Personalis?
Currently, no hedge funds are holding shares in PSNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (73.35% Upside)
$11.67 (73.35% Upside)
Blogger Sentiment
Bearish
PSNL Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 58.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
110.97%
12-Months-Change
Fundamentals
Return on Equity
-39.13%
Trailing 12-Months
Asset Growth
23.64%
Trailing 12-Months
Company Description
Personalis
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
PSNL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum (massive Clinical test growth, nearly 240% MRD biopharma revenue increase, two Medicare coverage wins, deepening evidence base and product innovation) alongside an intentional, transitional financial profile (legacy revenue wind-downs, margin compression from unreimbursed volume, higher operating losses and increased cash burn as the company scales). Management presented a clear strategy to trade near-term margins and higher cash usage for accelerated market share and reimbursement conversion, supported by a strong cash position and multiple validation points. Upside depends on further reimbursement rollouts (e.g., IO) and steady biopharma demand/timing.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$11.67
▲(73.35% Upside)
Technical Analysis
Ownership Overview
13.23% Insiders
14.28% Mutual Funds
4.08% Other Institutional Investors
53.61% Public Companies and
Individual Investors